Serial Magnetic Resonance Imaging in Patients with a First Clinical Episode Suggestive of Multiple Sclerosis: Outline of a Research Protocol

  • C. Pozzilli
  • P. Pantano
  • S. Di Legge
  • F. Caramia
  • M. C. Piattella
  • I. Pestalozza
  • W. Nucciarelli
  • A. Paolillo
  • L. Bozzao
  • G. L. Lenzi
Part of the Topics in Neuroscience book series (TOPNEURO)


The application of magnetic resonance imaging (MRI) in multiple sclerosis (MS) has provided powerful insights into the evolution of the disease process over time. MRI has an established role in the diagnosis and has also been used to investigate the natural course of the disease and to monitor treatment effects in clinical trials [1].


Multiple Sclerosis Apparent Diffusion Coefficient Expand Disability Status Scale Optic Neuritis Brain Magnetic Resonance Imaging 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Miller DH, Grossmann RI, Reingold SC, McFarland HF (1999) The role of magnetic resonance techniques in understanding and managing multiple sclerosis. Brain 121:3–1224CrossRefGoogle Scholar
  2. 2.
    Jacobs L, Kinkel PR, Kinkel WR (1986) Silent brain lesions in patients with isolated idiopathic optic neuritis. A clinical and nuclear magnetic resonance imaging study. Arch Neurol 43:452–455PubMedCrossRefGoogle Scholar
  3. 3.
    Ormerod IE et al (1987) The role of NMR imaging in the assessment of multiple sclerosis and isolated neurological lesions. A quantitative study. Brain 110:1579–1616PubMedCrossRefGoogle Scholar
  4. 4.
    Ford B, Tampieri D, Francis G (1992) Long-term follow-up of acute partial transverse myelopathy. Neurology 42:250–252PubMedCrossRefGoogle Scholar
  5. 5.
    Brex PA et al (1999) Multisequence MRI in clinically isolated syndromes and the early development of MS. Neurology 53:1184–1190PubMedCrossRefGoogle Scholar
  6. 6.
    Morrissey SP et al (1993) The significance of brain magnetic resonance imaging abnormalities at presentation with clinically isolated syndromes suggestive of multiple sclerosis. A 5-year follow-up study. Brain 116:135–146PubMedCrossRefGoogle Scholar
  7. 7.
    Beck RW et al (1993) The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis. The Optic Neuritis Study Group. N Engl J Med 329:1764–1769PubMedCrossRefGoogle Scholar
  8. 8.
    Filippi M et al (1994) Quantitative brain MRI lesion load predicts the course of clinically isolated syndromes suggestive of multiple sclerosis. Neurology 44:635–641PubMedCrossRefGoogle Scholar
  9. 9.
    O’Riordan JI et al (1998) The prognostic value of brain MRI in clinically isolated syndromes of the CNS. A 10-year follow-up. Brain 121:495–503PubMedCrossRefGoogle Scholar
  10. 10.
    Sailer M et al (1999) Quantitative MRI in patients with clinically isolated syndromes suggestive of demyelination. Neurology 52:599–606PubMedCrossRefGoogle Scholar
  11. 11.
    Barkhof F et al (1997) Comparison of MRI criteria of first presentation to predict conversion to clinically definite multiple sclerosis. Brain 120:2059–2069PubMedCrossRefGoogle Scholar
  12. 12.
    McFarland HF et al (1992) Using gadolinium-enhanced magnetic resonance imaging lesions to monitor disease activity in multiple sclerosis. Ann Neurol 32:758–766PubMedCrossRefGoogle Scholar
  13. 13.
    Kappos L et al (1999) Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysis. Gadolinium MRI Meta-analysis Group. Lancet 353:964–969PubMedCrossRefGoogle Scholar
  14. 14.
    Kinkel RP, Simon JH, Baron B (1999) Bimonthly cranial MRI activity following an isolated demyelinating syndrome: potential outcome measures for future multiple sclerosis ‘prevention’ trials. Mult Sci 5:307–312Google Scholar
  15. 15.
    Jacobs LD, Beck RW, Simon JH et al (2000) Intramuscular interferon beta la-therapy initiated during a first demyelinating event in multiple sclerosis. N Engl J Med 343:898–904PubMedCrossRefGoogle Scholar
  16. 16.
    Comi G, Filippi M, Barkhof F et al (2001) Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 357:1576–1582PubMedCrossRefGoogle Scholar
  17. 17.
    Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33:1444–1452PubMedCrossRefGoogle Scholar
  18. 18.
    Fazekas F et al (1988) Criteria for an increased specificity of MRI interpretation in elderly subjects with suspected multiple sclerosis. Neurology 38:1822–1825PubMedCrossRefGoogle Scholar
  19. 19.
    Poser CM et al (1983) New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 13:227–231PubMedCrossRefGoogle Scholar
  20. 20.
    Filippi M et al (1998) A multi-centre longitudinal study comparing the sensitivity of monthly MRI after standard and triple dose gadolinium-DTPA for monitoring disease activity in multiple sclerosis. Implications for phase II clinical trials. Brain 21:2011–2020CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Italia 2004

Authors and Affiliations

  • C. Pozzilli
  • P. Pantano
  • S. Di Legge
  • F. Caramia
  • M. C. Piattella
  • I. Pestalozza
  • W. Nucciarelli
  • A. Paolillo
  • L. Bozzao
  • G. L. Lenzi

There are no affiliations available

Personalised recommendations